Antineoplastic treatment with crizotinib during pregnancy: a case report
Files
Publication date
2019-01
Authors
Jensen, Kristian H
Persson, Gitte
Storgaard, Lone
Nielsen, Birgitte B
Pedersen, Berit W
Maroun, Lisa L
Huitema, Alwin D R
Pøhl, Mette
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.
Keywords
Crizotinib/therapeutic use, Pregnancy, Pregnancy Complications, Neoplastic/drug therapy, Humans, Lung Neoplasms/drug therapy, Antineoplastic Agents/therapeutic use, Fatal Outcome, HELLP Syndrome/etiology, Adult, Female, Adenocarcinoma of Lung/drug therapy, Taverne, Hematology, Oncology, Radiology Nuclear Medicine and imaging, Case Reports, Letter
Citation
Jensen, K H, Persson, G, Storgaard, L, Nielsen, B B, Pedersen, B W, Maroun, L L, Huitema, A & Pøhl, M 2019, 'Antineoplastic treatment with crizotinib during pregnancy : a case report', Acta Oncologica, vol. 58, no. 1, pp. 121-122. https://doi.org/10.1080/0284186X.2018.1497302